Proton-pump inhibitors were associated with reduced effectiveness of alendronate for preventing hip fractures

Ito, Kouta
October 2011
ACP Journal Club;10/18/2011, Vol. 155 Issue 4, p12
Academic Journal
The article discusses a study which investigated whether proton-pump inhibitors (PPIs) reduce the effectiveness of alendronate for preventing hip fractures. The study was conducted in Denmark and involved 38,088 patients who started alendronate between 1996 and 2005. It was found that concurrent use of proton-pump inhibitors was linked to reduced effectiveness of alendronate for preventing hip fractures in older adults.


Related Articles

  • 2011 - Proton-pump inhibitors were associated with reduced effectiveness of alendronate for preventing hip fractures. Ito, Kouta // ACP Journal Club;10/18/2011, Vol. 155 Issue 4, p12 

    The article discusses a study which examined the impact of proton-pump inhibitors (PPIs) on the effectiveness of alendronate for preventing hip fractures. The study included 38,088 patients who are under alendronate treatment regimen between 1996 and 2005. It concluded that concurrent use of...

  • Latest Research.  // Medical Economics;7/25/2011, Vol. 88 Issue 14, p55 

    The article presents abstracts on medical topics which include the use of proton-pump inhibitors (PPIs) which reduces alendronate's efficacy to reduce hip fracture risk in old patients, treatment of rheumatoid arthritis (RA) and psoriasis with disease-modifying antirheumatic drugs (DMARDs) which...

  • Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women. Papapoulos, Socrates E.; Quandt, Sara A.; Liberman, Uri A.; Hochberg, Marc C.; Thompson, Desmond E. // Osteoporosis International;May2005, Vol. 16 Issue 5, p468 

    Treatment with alendronate, a potent and specific inhibitor of bone resorption, is known to significantly reduce fracture risk among women with postmenopausal osteoporosis. The purpose of this metaanalysis was to assess the consistency of the effect of alendronate in reducing the risk of hip...

  • Alendronate in the Treatment of Osteoporosis: A Review of the Clinical Trials. Siris, Ethel // Journal of Women's Health & Gender-Based Medicine;Jul/Aug2000, Vol. 9 Issue 6, p599 

    Osteoporosis is a highly prevalent disease. More than half of postmenopausal women will experience fractures. Women at high risk (osteoporosis as measured by bone density, low trauma fractures of any type, or certain other risk factors) often require pharmacological therapy. However, surveys...

  • The Effect of Alendronate on Fracture-Related Healthcare Utilization and Costs: The Fracture Intervention Trial. Chrischilles, E. A.; Dasbach, E. J.; Rubenstein, L. M.; Cook, J. R.; Tabor, H. K.; Black, D. M. // Osteoporosis International;Sep2001, Vol. 12 Issue 8, p654 

    The Vertebral Fracture Arm (VFA) of the Fracture Intervention Trial (FIT) study demonstrated that alendronate reduced the incidence of spine, forearm and hip fractures in women with low bone mass and existing vertebral fractures by about 50%. The objective of the present study was to determine...

  • Medical treatment of vertebral osteoporosis. Lippuner, K. // European Spine Journal;Oct2003 Supplement 2, Vol. 12, pS132 

    Although osteoporosis is a systemic disease, vertebral fractures due to spinal bone loss are a frequent, sometimes early and often neglected complication of the disease, generally associated with considerable disability and pain. As osteoporotic vertebral fractures are an important predictor of...

  • Bisphosphonates in the management of thalassemia-associated osteoporosis: a systematic review of randomised controlled trials. Giusti, Andrea // Journal of Bone & Mineral Metabolism;Nov2014, Vol. 32 Issue 6, p606 

    Bisphosphonates are potent inhibitors of bone resorption, widely used for the management of osteoporosis and fracture prevention. Recent evidence suggests that bisphosphonates may have beneficial effects in the treatment of thalassemia-associated osteoporosis, a complex and multifactorial...

  • Proton-pump inhibitors and risk of fractures: an update meta-analysis. Zhou, B.; Huang, Y.; Li, H.; Sun, W.; Liu, J. // Osteoporosis International;Jan2016, Vol. 27 Issue 1, p339 

    Summary: To identify the relationship between proton-pump inhibitors (PPIs) and the risk of fracture, we conducted an update meta-analysis of observational studies. Results showed that PPI use was associated with a modestly increased risk of hip, spine, and any-site fracture. Introduction: Many...

  • Alendronate: An Update of its Use in Osteoporosis. Sharpe, M.; Noble, S.; Spencer, C.M. // Drugs;May2001, Vol. 61 Issue 7, p999 

    Alendronate (alendronic acid) is a nitrogen-containing bisphosphonate which binds to bone surfaces and inhibits bone resorption by osteoclasts. Oral alendronate 5 or 10 mg/day produces sustained increases in bone mineral density (BMD) in postmenopausal women with or without osteoporosis, in men...


Read the Article


Sign out of this library

Other Topics